Ocular Therapeutix™ Reports Third Quarter 2019 Financial Results and Business Update
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the third quarter ended September 30, 2019 and provided a business update. “We have had very productive quarter,” said Antony Mattessich, President and Chief Executive Officer. “As we had hoped, the first phase of our DEXTENZA laun